Press Release
September 14, 2026

Renault Group welcomes Moody’s 
upgrade to investment grade ‘Baa3’

  • Moody’s upgrades Renault SA to an investment grade long-term credit rating ‘Baa3’ with a stable outlook
  • The upgrade recognizes Renault Group’s in-depth transformation and the resilience of its business model, supported notably by its value-driven commercial policy, partnership approach focused on ROCE and dual electrification strategy
  • It also reflects Renault Group’s prudent financial management, disciplined and balanced capital allocation, robust cash generation, solid liquidity profile and reinforced balance sheet

Boulogne-Billancourt, France, September 14, 2026 – Renault Group welcomes Moody’s decision to upgrade Renault SA’s long-term credit rating to investment grade ‘Baa3’ with a stable outlook, from ‘Ba1’ with a positive outlook. This upgrade is aligned with the strategic priorities set out in futuREady, which builds on strong fundamentals and aims to turn a success story into a success system.
It recognizes the in-depth transformation carried out by Renault Group and the progress achieved in strengthening its business and financial profiles.

The resilience of its business model is underpinned by a disciplined commercial policy, a selective partnership approach and a smart electrification strategy combining a dual expertise in electric vehicles and full hybrids. It also reflects how Mobilize Financial Services further amplifies automotive value creation through a virtuous captive model that drives financing, leasing, insurance, services and customer loyalty, particularly relevant to support the electrification trend of Renault Group’s automotive activity.

The investment-grade financial profile of Renault Group reflects its disciplined execution, prudent financial management, balanced capital allocation, robust cash generation, solid liquidity profile and reinforced balance sheet. These elements are supporting its ability to pursue consistent and predictable value creation in a challenging automotive environment.

The press release by Moody’s can be accessed via their homepage: https://www.moodys.com/.

RENAULT GROUP
PRESS CONTACT
François Rouget
+33 6 23 68 07 88
francois.rouget@renault.com
RENAULT GROUP 
INVESTOR RELATIONS
Florent Chaix
+33 6 07 88 83 05
florent.chaix@renault.com

About Renault Group

Renault Group is at the forefront of a mobility that is reinventing itself. The Group relies on the complementarity of its three automotive brands – Renault, Dacia, Alpine – and its financial captive – Mobilize Financial Services – to offer sustainable and innovative mobility solutions to its customers. Established in more than 100 countries, Renault Group sold 2.337 million vehicles in 2025. It employs more than 100,000 people who embody its Purpose every day, so that mobility brings people closer.
Ready to pursue challenges both on the road and in competition, the Group is committed to an ambitious and value-generating transformation focused on the development of new technologies and services, and a new range of even more competitive, balanced, and electrified vehicles. In line with environmental challenges, Renault Group’s ambition is to achieve Net Zero carbon in Europe by 2040 and worldwide by 2050. 

More information: https://www.renaultgroup.com/en/

Attachment

PRESS
RELEASE

NANTERRE, France
Monday 14 September 2026

Disclosure of Transactions in Own Shares

In accordance with the authorizations given by the shareholders’ general meeting on 4 June 2026, to trade on its shares and pursuant to applicable law on share repurchase, FORVIA (LEI: 969500F0VMZLK2IULV85) declares the following purchases of its own shares (FR0000121147) from 7 to 10 September 2026:

Aggregated Presentation by Day and by Market

Transaction date Daily total volume (in number of shares) Daily weighted average price of shares acquires (in EUR/share) Market (MIC code)
07/09/2026 104,117 9.8483 XPAR
07/09/2026 39,891 9.8373 CEUX
07/09/2026 7,106 9.8500 TQEX
07/09/2026 6,886 9.8616 AQEU
08/09/2026 124,892 9.8661 XPAR
08/09/2026 30,524 9.8675 CEUX
08/09/2026 4,897 9.8541 TQEX
08/09/2026 4,687 9.8974 AQEU
09/09/2026 80,104 9.6613 XPAR
09/09/2026 49,896 9.6286 CEUX
09/09/2026 10,000 9.6378 TQEX
09/09/2026 10,000 9.6353 AQEU
10/09/2026 98,837 9.8747 XPAR
10/09/2026 34,371 9.8682 CEUX
10/09/2026 6,891 9.8609 TQEX
10/09/2026 6,901 9.8683 AQEU

Press Analysts
Christophe MALBRANQUE
Directeur Influence Groupe
+33 (0) 6 21 96 23 53
christophe.malbranque@forvia.com
Adeline MICKELER
Group Vice President Investor Relations
+33 (0) 6 61 30 90 90
adeline.mickeler@forvia.com
Audrey ÉPÈCHE
Head of Media Relations
+33 (0) 6 15 98 23 53
audrey.epeche@forvia.com
Sébastien LEROY
Group Deputy Investor Relations Director
+33 (0) 6 26 89 33 69
sebastien.leroy@forvia.com

FORVIA, a global automotive technology supplier, comprises the complementary technology and industrial strengths of Faurecia and HELLA. With over 137 500 people, including more than 12,000 R&D engineers across 40+ countries, FORVIA provides a unique and comprehensive approach to the automotive challenges of today and tomorrow. Composed of 6 business groups and a strong IP portfolio of over 12,400 patents, FORVIA is focused on becoming the preferred innovation and integration partner for OEMs worldwide. In 2025, the Group achieved a consolidated revenue of 26.2 billion euros prior to IFRS 5. FORVIA SE is listed on the Euronext Paris market under the FRVIA mnemonic code and is a component of the SBF 120 index. FORVIA aims to be a change maker committed to foreseeing and making the mobility transformation happen. www.forvia.com

Attachment

Í samræmi við skilmála skuldabréfsins SIL 23 1 munu vextir skuldabréfsins fyrir tímabilið 20. september til 19. desember verða 11,8%.

Upplýsingar um undirliggjandi lánasafn þann 14. september 2026:

  Óverðtryggt Verðtryggt
Vegnir meðalvextir 12,2% 6,6%
Hlutfall fjárfestingareigna 51% 49%

Nánari upplýsingar veitir Fríða Einarsdóttir, frida.einarsdottir@stefnir.is

Í samræmi við skilmála skuldabréfsins SIL 35 6 munu vextir skuldabréfsins fyrir tímabilið 20. september til 19. desember verða 11,8%.

Upplýsingar um undirliggjandi lánasafn þann 14. september 2026:

  Óverðtryggt Verðtryggt
Vegnir meðalvextir 11,9% 5,9%
Hlutfall fjárfestingareigna 74% 26%

Nánari upplýsingar veitir Fríða Einarsdóttir, frida.einarsdottir@stefnir.is

Toronto, Ontario, Sept. 14, 2026 (GLOBE NEWSWIRE) — Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC: BLGVF) (FRA: ECA) (the “Corporation” or “Belgravia”) announces its intention to adopt the policies outlined in the Semi-Annual Reporting (” SAR “) Pilot Program utilizing the exemptions provided under Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the ” Blanket Order “).

The SAR Pilot program is implemented under the Blanket Order, which allows eligible venture issuers to voluntarily move from quarterly to semi-annual financial reporting. By adopting the SAR Program, the Company aims to reduce the administrative and financial burden associated with quarterly reporting.

The Company will not file interim financial statements and related Management Discussion and Analysis for the three and nine-month period ending September 30, 2026.

The Company will continue to file audited annual financial statements (due within 120 days of December 31) and six-month interim financial reports (due within 60 days of June 30).

The Company confirms it meets the pilot program’s eligibility criteria, which include being a venture issuer with annual revenues of less than $10 million and maintaining a clean 12-month continuous disclosure record. The Company remains committed to timely disclosure and will continue to report all material changes and significant developments as required under National Instrument 51-102 – Continuous Disclosure Obligations.

The Company confirms that this news release is being filed pursuant to Coordinated Blanket Order 51 – 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.

About Belgravia Hartford Capital Inc.

Belgravia Hartford Capital Inc. is an investment issuer focused on technology, finance, artificial intelligence, digital assets and related investment opportunities. Listed for trading on the Canadian Securities Exchange and OTCQB, the Company is focused on the technology and finance sectors of the Bitcoin ecosystem. The Company’s 2018 Investment Policy specifies cryptocurrencies, artificial intelligence, media and digital streaming opportunities.

Belgravia invests in a portfolio of private and public companies located in jurisdictions governed by the rule of law. Belgravia and its investments are considered very high-risk holdings and may expose shareholders to significant volatility and losses.

Forward-Looking Statements and Disclaimer

This news release contains certain forward-looking statements, including statements regarding the Company’s eligibility to participate in and continue to rely on the SAR Pilot Program, its intention to adopt semi-annual reporting and the anticipated benefits of doing so.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such statements. They are generally identified by terminology such as “may,” “will,” “expect,” “anticipate,” “believe,” “continue” and “potential,” including the negative or other variations of such terms or comparable terminology.

These statements are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including changes in market trends, the impact of general economic and industry conditions, dependence upon regulatory and governmental approvals, and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in preparing such information, although considered reasonable at the time of preparation, may prove to be imprecise. Accordingly, undue reliance should not be placed on forward-looking statements.

The Company undertakes no obligation to update any forward-looking statement, except as required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information: For More Information, Please Contact: Mehdi Azodi, President & CEO, Belgravia Hartford Capital Inc., (416) 779- 3268, mazodi@blgv.ca CO: Belgravia Hartford Capital Inc.

               

Company announcement No. 48 / 2026

Zealand Pharma – Transactions related to share buy-back program (week 37, 2026)

Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 37 (September 7 – September 11, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.

Transactions executed in week 37
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 37 (September 7, 2026 – September 11, 2026):

Date Number of shares Average purchase price (DKK) Transaction value (DKK)
Accumulated as per latest announcement 3,046,000   924,481,620
07/09/2026  27,000  306.70  8,280,900
08/09/2026  37,000  300.55  11,120,350
09/09/2026  50,000  291.93  14,596,500
10/09/2026  70,000  287.04  20,092,800
11/09/2026  70,000  282.46  19,772,200
Accumulated (W37) 254,000   73,862,750
Total accumulated
under the Program
3,300,000   998,344,370


Treasury shares and share capital

Following the transactions described above, Zealand Pharma holds a total of 4,170,842 treasury shares, corresponding to approximately 5.82% of the Company’s share capital.

The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.

Additional information
Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com

Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com

Andreas Hylleberg Mølleskov (Media) 
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com

Attachment

PITTSBURGH, Sept. 14, 2026 (GLOBE NEWSWIRE) — L.B. Foster Company (NASDAQ: FSTR), a global technology solutions provider of products and services for the rail and infrastructure markets, has announced the expansion of its European distribution capabilities through a strengthened partnership with global logistics provider Expeditors International, supporting L.B. Foster’s long-term growth strategy across the continent.

As demand for rail and infrastructure solutions continues to grow across Europe, L.B. Foster is investing in its supply chain capabilities to better serve customers, improve delivery performance, and support customers’ operational and sustainability objectives.

With more than a decade of successful collaboration, L.B. Foster has appointed Expeditors as its strategic distribution partner for mainland Europe, establishing a new distribution hub in Germany. The initiative is designed to streamline product delivery, improve supply chain resilience, and enhance the overall customer experience across key European markets.

The partnership with Expeditors further strengthens a long-standing collaboration and supports continued growth across European markets.

As customer expectations and supply chain requirements continue to evolve, strong partnerships, resilient operations, and reliable customer service remain critical factors for sustainable success.

By combining L.B. Foster’s industry expertise with a comprehensive global logistics network, local market knowledge, dedicated customer support, and supply chain capabilities, a scalable distribution platform has been established. The objective is to bring products closer to customers, improve availability and responsiveness, and simplify logistics processes across mainland Europe.

The collaboration reflects a shared commitment with Expeditors in creating long-term value through operational excellence, supply chain resilience, and strategic investment in logistics capabilities. It is designed to support growth across markets, industries, and product segments while enhancing service levels for customers throughout the region.

Expeditors Germany central location and well-developed logistics infrastructure provide a strong foundation for this initiative. The partnership is expected to support efficient distribution, strengthen operational performance, and create lasting value for L.B. Foster and its customers across Europe.

Jason Bowlin, Senior Vice President, Rail, L.B. Foster, said:

“As customer expectations continue to evolve, efficient, reliable, and resilient supply chains have never been more important. Strengthening our partnership with Expeditors enables us to better support our European customers by removing many of the logistical challenges that have emerged following the UK’s exit from the European Union.

This new distribution model is designed to help reduce delays, simplify customs and commercial processes, and improve overall delivery performance. Ultimately, it reinforces our ability to provide the high levels of service our customers expect while supporting our growth ambitions across the European market.”

John Austin, Head of Segment – Friction Management, Europe, L.B. Foster, added:

“We are targeting operational readiness in the fourth quarter and look forward to supporting our customers with faster and more efficient product availability. This initiative will help customers keep critical railway, industrial and mining operations running smoothly while improving responsiveness across the region.

Germany was selected as our European distribution hub due to its central location, strong transport infrastructure, and growing customer relationships throughout the Alpine region. The investment positions us closer to our customers and provides a strong platform for sustainable long-term growth.”

The expanded distribution capability represents another significant milestone in L.B. Foster’s commitment to investing in Europe and strengthening the support provided to customers operating some of the continent’s most critical transportation infrastructure networks.

Forward-Looking Statements

This release may contain “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements provide management’s current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements. Forward-looking statements in this earnings release are based on management’s current expectations and assumptions about future events that involve inherent risks and uncertainties and may concern, among other things, the Company’s expectations relating to our strategy, goals, projections, valuations and impairments, and plans regarding our financial position, liquidity, capital resources, results of operations and decisions regarding our strategic growth initiatives, market position, and product development. While the Company considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. The Company cautions readers that various factors could cause the actual results of the Company to differ materially from those indicated by forward-looking statements. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Among the factors that could cause the actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to: adverse economic conditions in the markets we serve, including recession, the volatility in the prices for oil and gas, tariffs, duties or trade wars, inflation, rising labor costs, project delays, and budget shortfalls, or otherwise; the disruption of government funding programs as a result of potential periodic government shutdowns; volatility in the global capital markets, including interest rate fluctuations, which could adversely affect our ability to access the capital markets on terms that are favorable to us; restrictions on our ability to draw on our credit agreement, including as a result of any future inability to comply with restrictive covenants contained therein; a decrease in freight or transit rail traffic; environmental matters and the impact of environmental regulations, including any costs associated with any remediation and monitoring of such matters; the risk of doing business in international markets, including compliance with anti-corruption and bribery laws, foreign currency fluctuations and inflation, global shipping disruptions, the imposition of increased or new tariffs, and trade restrictions or embargoes, or uncertainties relating to the imposition and enforcement of tariffs; our ability to timely effectuate our strategy, including cost reduction initiatives, and our ability to effectively integrate acquired businesses or to divest businesses, and to realize anticipated synergies and benefits; costs of and impacts associated with shareholder activism; the timeliness, cost, and availability of materials from our major suppliers, as well as the impact on our access to supplies of customer preferences as to the origin of such supplies, such as customers’ concerns about conflict minerals; labor disputes; emerging technologies, including those related to or arising from artificial intelligence, and resultant risks to our business and operations; cybersecurity risks such as data security breaches, malware, ransomware, “hacking,” and identity theft, either with respect to our systems or those of third parties on whom we rely, which could disrupt our business and may result in misuse or misappropriation of confidential or proprietary information, and could result in the disruption or damage to our systems, increased costs and losses, or an adverse effect to our reputation, business or financial condition; the continuing effectiveness of our ongoing implementation of an enterprise resource planning system; changes in current accounting estimates and their ultimate outcomes; the adequacy of internal and external sources of funds to meet financing needs, including our ability to negotiate any additional necessary amendments to our credit agreement or the terms of any new credit agreement, the Company’s ability to manage its working capital requirements and indebtedness; domestic and international taxes, including estimates that may impact taxes; domestic and foreign government regulations, including tariffs; our ability to maintain effective internal controls over financial reporting and disclosure controls and procedures; any change in policy or other change due to the results of the UK’s parliamentary elections and the U.S. presidential and congressional elections that could affect UK or US business conditions; other geopolitical conditions, including the ongoing conflicts between Russia and Ukraine, conflicts in the Middle East, and increasing tensions between China and Taiwan; a lack of, freezing of, or delay in state or federal funding for infrastructure projects; an increase in manufacturing or material costs, including volatility in steel prices, oil prices, and wage inflation; the loss of future revenues from current customers; any future global health crises, and the related social, regulatory, and economic impacts and the response thereto by the Company, our employees, our customers, and national, state, or local governments, including any governmental travel restrictions; and risks inherent in litigation and the outcome of litigation and product warranty claims. Should one or more of these risks or uncertainties materialize, or should the assumptions underlying the forward-looking statements prove incorrect, actual outcomes could vary materially from those indicated. Significant risks and uncertainties that may affect the operations, performance, and results of the Company’s business and forward-looking statements include, but are not limited to, those set forth under Item 1A, “Risk Factors,” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, or as updated and/or amended by our other current or periodic filings with the Securities and Exchange Commission.

The forward-looking statements in this release are made as of the date of this release and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by the federal securities laws.

Marketing and Communications:
Meredith Faust
412-928-3400, and follow the prompts
investors@lbfoster.com

L.B. Foster Company
415 Holiday Drive
Suite 100
Pittsburgh, PA 15220

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by Nant Capital, LLC (“Nant”) with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the “Milestone Closing”) as described below.

At the Initial Closing, the Company sold (i) shares of the Company’s common stock (the “Private Placement Shares”) or, at the election of an investor, pre-funded warrants in lieu of such shares (“Pre-Funded Warrants”), and (ii) accompanying common stock purchase warrants (“Common Warrants”). Each unit consisting of one Private Placement Share and a Common Warrant to purchase one-half of one Private Placement Share (“Common Warrants”) was issued for $0.2825 (the “Share Unit Purchase Price”), and each unit consisting of one Pre-Funded Warrant to purchase one share of Common Stock and a Common Warrant to purchase one-half of one share of Common Stock was issued for $0.28217 (the “Pre-Funded Unit Purchase Price”). The aggregate gross proceeds and the aggregate number of Private Placement Shares, Pre-Funded Warrants and Common Warrants issued as part of the Initial Closing were approximately $11.3 million, and 16,502,870, 23,498,156 and 20,000,514, respectively.

The Company intends to use the net proceeds from the private placement to repay outstanding indebtedness and for working capital and general corporate purposes, including the continued development of its clinical programs, research and development, and general and administrative expenses. The Company also expects that the PIPE will advance PDS0301 (also referred to as PDS01ADC or NHS-IL12) into late-stage clinical development, based on recent promising interim Phase 2 clinical trial data in microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC), types of colorectal cancer that have not responded well to treatment with immunotherapy. Patients with MSS and pMMR mCRC with liver metastases historically have dire treatment outcomes, with median overall survival of less than 12 months.*  In a National Cancer Institute (NCI) led Phase 2 trial, the addition of PDS0301 to standard of care therapy in 22 patients was well tolerated, and demonstrated deep and long-lasting tumor shrinkage and survival, with 80% of patients surviving for at least 24 months.

At the Milestone Closing, which will be triggered by the Company’s submission of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with Nant to the FDA, Nant and AB Group Ltd. will be obligated to purchase and the Company will be obligated to issue to each of Nant and AB Group Ltd., shares of common stock or Pre-Funded Warrants in lieu thereof for an aggregate purchase price of $10,000,000 and $1,000,000, respectively, subject to the satisfaction or waiver of the applicable closing conditions. The number of securities purchased by any investor will be subject to a 19.9% beneficial ownership limitation.

In addition to the PIPE transaction, and for additional consideration, the Company granted  NantWorks, LLC, an affiliate of Nant, a one-year exclusive right to negotiate an exclusive license to PDS0101, the Company’s novel investigational human papilloma virus targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The option has a term of one year.

Effective as of the Initial Closing, Dr. Soon-Shiong and Mr. James Banaag, who currently serves the as chief financial officer of NantBio, Inc., will join the Company’s board of directors.

Dr. Soon-Shiong commented, “PDS Biotechnology is developing promising novel cancer vaccines and immunocytokines that have demonstrated the potential to harness the power of the immune system to transform cancer care.  This is an area of significant interest for me, and I am pleased to join the board of directors and to be able to contribute towards the advancement of these therapies that are aimed at addressing difficult-to-treat cancers.” 

Dr. Frank Bedu-Addo, founder and CEO of PDS Biotechnology stated, “We believe that the ongoing clinical trials of our IL-12 immunocytokine PDS0301 at the NCI strongly suggest that PDS0301 has the potential to advance the treatment of solid tumors with immunotherapy.  We also believe that clinical trials of our cancer vaccine platform demonstrate the potential to advance the field of targeted T cell immunotherapy. We are extremely pleased that Dr. Soon-Shiong and NantWorks share our belief in the promise of our immunotherapy platforms. Dr. Soon-Shiong is a highly accomplished physician scientist, biotechnology entrepreneur and investor who has developed successful cancer therapies including an FDA approved immunocytokine.  We are honored to welcome Dr. Soon-Shiong to the company’s board of directors.”

Dr. Soon-Shiong, is an internationally recognized physician, surgeon, scientist, and philanthropist who is the author of over 100 peer-reviewed scientific publications and over 500 patents issued worldwide. Dr. Soon-Shiong is the Executive Chairman of ImmunityBio (NASDAQ: IBRX), a company he founded in 2014. He also serves as Chairman of NantHealth (NASDAQ:NH), a transformational healthcare company converging biomolecular medicine and bioinformatics to simplify healthcare. He is also the Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. Dr. Soon-Shiong is also the Owner and Executive Chairman of the Los Angeles Times.

Dr. Soon-Shiong has founded and led global pharmaceutical companies, including American Pharmaceutical Partners, Abraxis BioScience and ImmunityBio. At Abraxis he developed Abraxane, which became the first protein nanoparticle drug for breast, lung, and pancreatic cancers. The drug achieved blockbuster status with annual sales exceeding a billion dollars. Dr. Soon-Shiong’s contribution to the advancement of the oncology field has been honored with the Distinguished Medical Science award by the Smithsonian National Museum of American History where Abraxane is now permanently housed. He has also been honored by the Vatican with the Pontifical Key Visionary Award.

Dr. Soon-Shiong received his medical degree at the University of Witwatersrand, Johannesburg, South Africa and continued his training in surgery at the University of California Los Angeles where he performed the first West Coast pancreas transplant and the world’s first encapsulated islet cell transplant. He is a practicing surgeon and an adjunct Professor of Surgery at UCLA and a visiting Professor at the Imperial College of London.

Born and raised during the apartheid era in South Africa, Dr. Soon-Shiong has lived in Los Angeles since 1980 and is a citizen of the United States.

The securities sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the Private Placement Shares and shares of the Company’s common stock underlying the Pre-Funded Warrants and Common Warrants (together, the “Warrant Shares”) sold in the PIPE. Any offering of the Private Placement Shares and Warrant Shares under the resale registration statement will only be made by means of a prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Company’s securities, nor shall there be any offer, solicitation, or sale of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The private placement was conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

* Aruquipa MPS et al, Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review; ecancer 2024, 18:1771 

About PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy. PDS Biotechnology also owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; the risk that the Milestone Closing may not be completed in a timely manner or at all; the failure to realize the anticipated benefits of the PIPE and the other transactions described in this press release; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:

Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

Gross Proceeds of $11.3 Million at Initial Closing

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction. The round was led by Nant Capital, LLC (“Nant”) with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the “Milestone Closing”) as described below.

At the Initial Closing, the Company sold (i) shares of the Company’s common stock (the “Private Placement Shares”) or, at the election of an investor, pre-funded warrants in lieu of such shares (“Pre-Funded Warrants”), and (ii) accompanying common stock purchase warrants (“Common Warrants”). Each unit consisting of one Private Placement Share and a Common Warrant to purchase one-half of one Private Placement Share (“Common Warrants”) was issued for $0.2825 (the “Share Unit Purchase Price”), and each unit consisting of one Pre-Funded Warrant to purchase one share of Common Stock and a Common Warrant to purchase one-half of one share of Common Stock was issued for $0.28217 (the “Pre-Funded Unit Purchase Price”). The aggregate gross proceeds and the aggregate number of Private Placement Shares, Pre-Funded Warrants and Common Warrants issued as part of the Initial Closing were approximately $11.3 million, and 16,502,870, 23,498,156 and 20,000,514, respectively.

The Company intends to use the net proceeds from the private placement to repay outstanding indebtedness and for working capital and general corporate purposes, including the continued development of its clinical programs, research and development, and general and administrative expenses. The Company also expects that the PIPE will advance PDS0301 (also referred to as PDS01ADC or NHS-IL12) into late-stage clinical development, based on recent promising interim Phase 2 clinical trial data in microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC), types of colorectal cancer that have not responded well to treatment with immunotherapy. Patients with MSS and pMMR mCRC with liver metastases historically have dire treatment outcomes, with median overall survival of less than 12 months.*  In a National Cancer Institute (NCI) led Phase 2 trial, the addition of PDS0301 to standard of care therapy in 22 patients was well tolerated, and demonstrated deep and long-lasting tumor shrinkage and survival, with 80% of patients surviving for at least 24 months.

At the Milestone Closing, which will be triggered by the Company’s submission of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with Nant to the FDA, Nant and AB Group Ltd. will be obligated to purchase and the Company will be obligated to issue to each of Nant and AB Group Ltd., shares of common stock or Pre-Funded Warrants in lieu thereof for an aggregate purchase price of $10,000,000 and $1,000,000, respectively, subject to the satisfaction or waiver of the applicable closing conditions. The number of securities purchased by any investor will be subject to a 19.9% beneficial ownership limitation.

In addition to the PIPE transaction, and for additional consideration, the Company granted  NantWorks, LLC, an affiliate of Nant, a one-year exclusive right to negotiate an exclusive license to PDS0101, the Company’s novel investigational human papilloma virus targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The option has a term of one year.

Effective as of the Initial Closing, Dr. Soon-Shiong and Mr. James Banaag, who currently serves the as chief financial officer of NantBio, Inc., will join the Company’s board of directors.

Dr. Soon-Shiong commented, “PDS Biotechnology is developing promising novel cancer vaccines and immunocytokines that have demonstrated the potential to harness the power of the immune system to transform cancer care.  This is an area of significant interest for me, and I am pleased to join the board of directors and to be able to contribute towards the advancement of these therapies that are aimed at addressing difficult-to-treat cancers.” 

Dr. Frank Bedu-Addo, founder and CEO of PDS Biotechnology stated, “We believe that the ongoing clinical trials of our IL-12 immunocytokine PDS0301 at the NCI strongly suggest that PDS0301 has the potential to advance the treatment of solid tumors with immunotherapy.  We also believe that clinical trials of our cancer vaccine platform demonstrate the potential to advance the field of targeted T cell immunotherapy. We are extremely pleased that Dr. Soon-Shiong and NantWorks share our belief in the promise of our immunotherapy platforms. Dr. Soon-Shiong is a highly accomplished physician scientist, biotechnology entrepreneur and investor who has developed successful cancer therapies including an FDA approved immunocytokine.  We are honored to welcome Dr. Soon-Shiong to the company’s board of directors.”

Dr. Soon-Shiong, is an internationally recognized physician, surgeon, scientist, and philanthropist who is the author of over 100 peer-reviewed scientific publications and over 500 patents issued worldwide. Dr. Soon-Shiong is the Executive Chairman of ImmunityBio (NASDAQ: IBRX), a company he founded in 2014. He also serves as Chairman of NantHealth (NASDAQ:NH), a transformational healthcare company converging biomolecular medicine and bioinformatics to simplify healthcare. He is also the Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. Dr. Soon-Shiong is also the Owner and Executive Chairman of the Los Angeles Times.

Dr. Soon-Shiong has founded and led global pharmaceutical companies, including American Pharmaceutical Partners, Abraxis BioScience and ImmunityBio. At Abraxis he developed Abraxane, which became the first protein nanoparticle drug for breast, lung, and pancreatic cancers. The drug achieved blockbuster status with annual sales exceeding a billion dollars. Dr. Soon-Shiong’s contribution to the advancement of the oncology field has been honored with the Distinguished Medical Science award by the Smithsonian National Museum of American History where Abraxane is now permanently housed. He has also been honored by the Vatican with the Pontifical Key Visionary Award.

Dr. Soon-Shiong received his medical degree at the University of Witwatersrand, Johannesburg, South Africa and continued his training in surgery at the University of California Los Angeles where he performed the first West Coast pancreas transplant and the world’s first encapsulated islet cell transplant. He is a practicing surgeon and an adjunct Professor of Surgery at UCLA and a visiting Professor at the Imperial College of London.

Born and raised during the apartheid era in South Africa, Dr. Soon-Shiong has lived in Los Angeles since 1980 and is a citizen of the United States.

The securities sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the Private Placement Shares and shares of the Company’s common stock underlying the Pre-Funded Warrants and Common Warrants (together, the “Warrant Shares”) sold in the PIPE. Any offering of the Private Placement Shares and Warrant Shares under the resale registration statement will only be made by means of a prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Company’s securities, nor shall there be any offer, solicitation, or sale of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The private placement was conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

* Aruquipa MPS et al, Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review; ecancer 2024, 18:1771 

About PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy. PDS Biotechnology also owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; the risk that the Milestone Closing may not be completed in a timely manner or at all; the failure to realize the anticipated benefits of the PIPE and the other transactions described in this press release; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:

Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

10.19 g/t AuEq over 10.50 m marks the highest-grade intercept of down-plunge extension

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Blue Jay Gold Corp. (TSXV: JAY) (OTCQB: JAYGF) (FSE: JAY) (“Blue Jay” or the “Company”), is pleased to announce the first assay results from its maiden 2026 diamond drill program at the Steller Gold Project (“Steller” or the “Project“) in the Yukon Territory. Hole SC26-003 returned 14.00 metres (m) of 6.15 grams per tonne (g/t) gold (Au) and 124 g/t silver (Ag), or 8.04 g/t gold equivalent (AuEq), from 495.00 m, including 10.50 m of 7.84 g/t Au and 154 g/t Ag (10.19 g/t AuEq). The intersection represents an approximate 32 m down-plunge extension of the mineralization intersected in drill hole SC21-027, which returned 14.8 m of 5.79 g/t Au and 100.9 g/t Ag in 20211. The results highlight continuity of the mineralization and its host structure across multiple intercepts, with room for further expansion. The system displays an intermediate sulfidation epithermal style comparable to giant districts such as Fresnillo, Zacatecas and Pachuca in Mexico. Intercepts extending from surface to over 500 m down dip demonstrate the continuity and scale potential of the Skukum Creek system. Initial drilling at Mt. Skukum, the site of historical gold production between 1986 and 1988, returned 0.5 m of 57.4 g/t Au and 44.1 g/t Ag from 160.8 m in hole MS26-001. The historical high-grade production at Mt. Skukum, combined with the presence of multiple undertested vein sets, points to resource growth potential on this target corridor. The Company has identified similar potential for expansion along strike at other target areas across the Project’s 170 km² land package.

“SC26-003 is the kind of result we underwrote when we bought this project,” said Geordie Mark, CEO of Blue Jay Gold. “It confirmed mineralization more than 30 metres down-plunge of SC21-027, drilled in 2021, with effectively the same width, grade and grade distribution. That is what continuity looks like: not just a string of separate hits, but a zone you can follow. We identified this area as being completely open to depth and down-plunge. That was the call, and we have delivered results that exemplify our thesis.”

Most exploration programs start with a blank map. Steller handed us one already partly drawn, aided by historical drilling, 7.5 kilometres of underground development, and a high-grade resource in the ground. What has never existed is a structural framework that explains where the grade goes, and a hydrothermal model that predicts where other mineralized systems could be.”

“Hyperspectral core logging is central to how we are building it,” added Mark. “We have now put roughly 18,000 metres of historical core through the scanner system, reading alteration mineral distribution and chemistry directly from the core ahead of assay results from the lab. It shows a consistent, zoned alteration envelope around the mineralized structures that points toward mineralization. Every metre we scan turns rock we already own into data we can use to refine targets.

At Mt. Skukum, our first hole returned a high-grade intercept at the site of the former Mt. Skukum mine, which produced gold between 1986 and 1988. Seeing grades of that order in our own first holes tells us the system at Steller is not confined to a single deposit.

We are only about 3 months after listing, and the picture we formed in due diligence of Steller is holding. Rigs are turning and assays are pending on further holes. Today’s results are the first assay confirmation that the framework we are building points the right way.”

Highlights

  • High-grade down-plunge extension at Rainbow Zone at Skukum Creek: 14.0 m of 6.15 g/t Au and 124.1 g/t Ag (8.04 g/t AuEq) from 495.0 m in SC26-003, including 10.50 m of 7.84 g/t Au and 154.0 g/t Ag (10.19 g/t AuEq), approximately 32 m below SC21-027 (14.8 m of 5.79 g/t Au, 100.9 g/t Ag) (Figure 1).
  • Mineralization is continuous within the structure between drill holes: SC26-003 returned essentially the same width and grade as SC21-027, which is >30 m up-plunge. The structure carries consistent gold and silver tenor between the two holes rather than occurring as isolated lenses.
  • Our interpretation, now drill-tested: we projected that this zone was open. SC26-003 is the first drilling phase to test it and has unearthed that reality.
  • Hyperspectral logging of 18,000 m of core has produced a vectoring tool: a consistent, zoned alteration envelope wrapped around the mineralized structures, measurable directly in core and applicable to material already in the core yard. It has generated new targets along the Skukum Creek Structural Corridor.
  • First drilling at Mt. Skukum returns high-grade gold: MS26-001 returned 0.5 m of 57.4 g/t Au from 160.8 m, on the site of the former Mt. Skukum gold mine, which recovered 77,790 ounces of gold between 1986 and 1988.
  • Initial batch of many: 5 holes are reported today, with assays pending for further holes that have been completed. Mineralization at Skukum Creek remains open down-plunge and along strike, and rigs are turning.
  1. 2026 Technical Report. TECHNICAL REPORT AND UPDATED MINERAL RESOURCE ESTIMATE OF THE STELLER GOLD PROJECT, WHITEHORSE MINING DISTRICT, YUKON TERRITORY, CANADA. P&E Mining Consultants Inc. Effective Date: Oct. 31, 2025. Cut-off: 3.0 g/t AuEq. Au: US$2,850/oz. Ag: US$34.20/oz. AuEq ratio = Au:Ag 85.6:1

Cross-section through the Rainbow zone that highlights the continuity of the Au-Ag mineralization, and the >30 metre down dip extension of SC-26-003 compared with the most proximal intersection (SC-21-027). Holes being surveyed during drilling.

Figure 1: Cross-section through the Rainbow zone that highlights the continuity of the Au-Ag mineralization, and the >30 metre down dip extension of SC-26-003 compared with the most proximal intersection (SC-21-027). Holes being surveyed during drilling.

Table 1: Assay Results

Location From (m) To (m) Au (g/t) Ag (g/t) AuEq (g/t)1 Interval (m)
Skukum Creek            
SC-26-003 495.00 509.00 6.15 124.0 8.04 14.00
including 498.50 509.00 7.84 154.0 10.19 10.50
And including 499.60 504.00 12.00 258.0 15.94 4.40
             
SC-26-001 444.63 448.96 4.63 74.0 5.76 4.33
SC-26-004* 377.00 378.00 1.15 0.2 1.15 1.00
             
Mt. Skukum            
MS (26-01) 160.80 161.30 57.40 44.1 58.07 0.50

This press release is reporting on the first three holes at Skukum Creek hole 1, 3 and 4 and holes 1 and 4a at Mt. Skukum which is 200 samples in total. True widths are estimated at approximately 60-80 % of the down-hole interval based on currently available results and observations. Interval average grades are calculated using un-capped assays. Composites are calculated using a 1.0 g/t AuEq cut-off grade with a maximum of 2.0 m of internal dilution of below-cut-off material and a minimum composite length of 1.0 m.

  1. Gold equivalent (AuEq) is calculated as AuEq (g/t) = Au (g/t) + [Ag (g/t)]*($67*0.93/$4300*0.95)], using US$4,300/oz gold and US$67.00/oz silver. Project recoveries of 95% for gold and 93% for silver and are consistent with the assumptions used in the Mineral Resource Estimate with an effective date of October 31, 2025. AuEq values are provided for comparison only and do not reflect payable metal.

Hole SC26-001 returned 4.33 m of 4.63 g/t Au and 74.0 g/t Ag (5.76 g/t AuEq) from 444.63 m to 448.96 m, lending further support to the continuity of mineralization at Skukum Creek. Hole SC26-004 deviated from its planned trajectory and did not reach its intended target, returning 1.00 m of 1.15 g/t Au and 0.2 g/t Ag (1.15 g/t AuEq) from 377.00 m to 378.00 m in a separate zone for subvertical Au-Ag mineralization. The Company plans to re-drill this target in a future phase of the program.

Skukum Creek Plan Section showing drill traces for initial holes from 2026, compared with historical holes on the Northeast portion of the deposit area. Note that SC-26-004 drill hole deviated off target and out of structural plane.

Figure 2: Skukum Creek Plan Section showing drill traces for initial holes from 2026, compared with historical holes on the Northeast portion of the deposit area. Note that SC-26-004 drill hole deviated off target and out of structural plane.

Table 2: Drill Hole Collar Locations

Hole ID East North Elevation Depth Dip Azimuth
SC-26-001 478102 6671141 1386 529 -52 300
SC-26-003 478102 6671141 1386 542 -56 307.5
SC-26-004 478102 6671141 1386 537 -56 314.5
MS-26-001 473531 6674889 1913 222 -66.5 065
MS-26-004A 473455 6674883 1916 213 -54 112


Next Steps

Drilling is ongoing. Follow-up holes are being planned to test further down-plunge and along strike continuity of mineralization on the Rainbow zone. Drill results are expected to be delivered from Skukum Creek and other target areas on Steller during and post the completion of the exploration program.

Drilling and Geology Discussion

Structural Setting and Controls on Mineralization

The 2026 Skukum Creek drill program is testing structural extensions to Au-Ag mineralization hosted within composite breccia-shear zones. These zones acted as fluid conduits and record multiple pulses of overprinting hydrothermal alteration, Au-(Ag) mineralization and coeval felsic to intermediate dyking, all formed during the Eocene. This system is comparable to major epithermal districts including Guanajuato, Pachuca-Real del Monte, Fresnillo and Tayoltita in Mexico, and the Comstock district in Nevada and Creede in Colorado in the United States. These districts share a similar Eocene-Oligocene age and formed within calderas and large volcanic complexes, comparable to the geological systems preserved across the Stellar project.

Rainbow Zone Down-Plunge Extension

The holes reported today are the first tranche of results from the 2026 program and test the down-plunge extension of the Rainbow Zone.

SC26-003 extends high-grade Au-Ag mineralization >30 m down-plunge of SC-21-027, drilled in 2021. The intersection grades 8.04 g/t AuEq. over 14 m and preserves the across-structure grade distribution seen up-plunge. Equally important, the holes confirm that the bounding structures are continuous and that they remained active as conduits through repeated pulses of hydrothermal alteration, mineralization and Eocene dyking. This dyking is comparable to that found in the Mexican examples of major intermediate sulfidation systems, which can extend more than 1 km vertically and 8 km along strike, forming multi-million AuEq systems that enjoyed protracted mining histories. Our framework exploration represents the first systematic integration of Steller’s historical data within the geological context of these major epithermal systems and the application of next generation geological tools (e.g., LithologIQ) to unravel Stellar’s potential.

Not to be overlooked, SC26-001 returned 4.33 metres grading 5.70 g/t AuEq. on the Rainbow Zone and importantly shows continuity of the structure that hosts mineralization. The Au-Ag mineralization is hosted within composition vein-breccia that is spatially associated with the same alteration patterns witnessed in SC26-003, as such we are developing an improved confidence in the hydrothermal evolution of this system.

Hyperspectral Core Logging and Alteration Zoning

Blue Jay has completed hyperspectral logging of approximately 18,000 m of archived drill core. The results show a consistent, zoned alteration envelope along and up-dip of the mineralized structures. Measured as down-hole lengths outward from the mineralized zone, the envelope grades from an outer white-mica-rich halo of more than 100 m, through an inner halo of up to 90 m in which chlorite becomes progressively more Fe-rich, to a proximal zone of tens of metres in which hydrothermal carbonate is Mg-rich.

The practical value is vectoring. The zoning is measurable in core, it repeats across holes, and it can be applied to material already in the core yard. It has generated new targets within the strike length of the mineralized corridor. This begins to define the scale potential for multiple target areas that warrant broad step out drilling.

The Skukum Creek Structural Corridor

Skukum Creek mineralization is currently defined over a strike length of more than 1 km. It sits within the Skukum Creek Structural Corridor, which extends for more than 15 km as defined by regional magnetic data and comprises a zone of multiple sub-parallel and curvilinear structures: the continuity and distribution of these structures were unmapped before magnetics could be interrogated.

These structures are interpreted as second order features relative to a longer-wavelength, north-south trending, deeper penetrative structure that shows spatial association with Eocene dyke swarms. Both the corridor length and the structural hierarchy are interpretations drawn from airborne magnetics, that was reprocessed and reinterpreted in 2026.

District-Scale Associations

The same spatial and temporal associations between alteration, mineralization, dyking and dilation are seen at Raca, at Goddell Gully, and more broadly across the Tellurium-rich, low sulphidation epithermal vein field at Mt. Skukum. North-south and east-west trending composite dyke swarms are documented across that field and around Skukum Creek, Raca, Chieftain and Goddell. Comparable associations are mapped historically along east-west trending composite dyke sets of rhyolitic, andesitic and quartz-feldspar porphyry composition east of Skukum Creek, where copper- and molybdenum-bearing mineralization is also present.

At depth in the altered footwall of the Rainbow Zone, a sub-population of quartz-pyrite-molybdenite veins has been documented. These form part of a hydrothermal evolution progressing from early potassic alteration, through localized magnetite alteration and sericite-quartz-chlorite alteration, to Au-Ag mineralization with Mg-rich carbonate, and finally to late low-temperature epithermal quartz veining. This progressive hydrothermal, magmatic and chemical evolution bears similarities to the geological systems documented in Guanajuato and Creede Colorado.

That progression, together with the copper-molybdenum mineralization east of Skukum Creek and the quartz-feldspar porphyry dykes, is interpreted as consistent with hydrothermal centres being driven by magmatic intrusions at depth. No drilling has ever tested that integrated interpretation, and no such target construction has been defined before.

Oriented Core

Oriented core is being collected at Steller and will be used for the first time in the property’s history. It is one of the defining elements of this framework year of exploration and gives Blue Jay the capacity to target future drilling across a project that shows district-scale mineralization with broad commonalities within a major regional architecture.

Market Making Engagement

The Company announces that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its proprietary algorithm, ICP Premium® in compliance with the policies and guidelines of the TSX Venture Exchange (the “Exchange”) and other applicable legislation. ICP will be paid a monthly fee of C$7,500, plus applicable taxes. The agreement between the Company and ICP was signed with a start date of September 10th, 2026, and is for four (4) months (the “Initial Term”) and shall be automatically renewed for subsequent one (1) month terms (each month called an “Additional Term”) unless either party provides at least thirty (30) days written notice prior to the end of the Initial Term or an Additional Term, as applicable. There are no performance factors contained in the agreement and no stock options or other compensation in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future. The Company’s engagement of ICP remains subject to the approval of the Exchange.

ICP is an arm’s length party to the Company. ICP’s market making activity will be primarily to correct temporary imbalances in the supply and demand of the Company’s shares. ICP will be responsible for the costs it incurs in buying and selling the Company’s shares, and no third party will be providing funds or securities for the market making activities.

Quality Assurance and Quality Control

Drill core was transported from the drill platform to the logging facility where it was logged, photographed, and samples split by diamond saw. Samples were then bagged, and a blank, duplicate or certified reference material inserted into the sample stream every 10 samples. Samples were submitted by hole, and placed in large sacks, sealed with numbered tags in order to maintain a chain-of-custody, and transported to ALS Laboratories in Whitehorse, Yukon where they were shipped by ALS to the prep and analytical lab in North Vancouver, British Columbia.

Individual samples were crushed to 2mm (10 mesh) and a 250g split was ground until at least 85% of the material passes through a 75-micron (75 µm / <200 mesh) screen. Samples were prepared for analysis according to ALS method ME-MS61 where multi-element (48) geochemical analysis was performed by four-acid digest of a 0.25g split followed by a combination of ICP-AES and ICP-MS finishes. Over-limits for gold and silver samples were re-analyzed using ALS method ME-GRA21 where a 30g split is analyzed with fire assay and gravimetric finish.

All results passed the QA/QC screening at the lab, all company inserted standards and blanks returned results that were within acceptable limit.

Qualified Person

The scientific and technical content of this news release has been reviewed and approved by Freeman Smith, P.Geo., VP Exploration of Blue Jay Gold Corp., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About ICP Securities Inc.

ICP Securities Inc. is a Toronto based CIRO dealer-member that specializes in automated market making and liquidity provision, as well as having a proprietary market making algorithm, ICP Premium®, that enhances liquidity and quote health. Established in 2023, with a focus on market structure, execution, and trading, ICP has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors.

About Blue Jay Gold Corp.

Blue Jay Gold Corp. is a Canadian gold exploration company focused on growing and discovering resources within established gold producing regions in Canada. The Company’s flagship asset is the 100%-owned Steller Gold Project in southern Yukon, an infrastructure-supported, past-producing mine with significant exploration upside and clear near-term catalysts. Blue Jay has also built a portfolio of projects in Ontario. With strategically located assets and a leadership team experienced in geology and capital markets, Blue Jay will advance disciplined, modern exploration programs focused on target definition, resource growth, and new discoveries in known gold-mineralized regions. For more information, please visit: www.bluejaygoldcorp.com.

ON BEHALF OF BLUE JAY GOLD CORP.

signed “Geordie Mark”
Geordie Mark, CEO

For additional information contact:

BLUE JAY GOLD CORP.

Geordie Mark
CEO
Blue Jay Gold Corp.
info@bluejaygoldcorp.com
Phone: (604) 235-4059
Eric Negraeff
Investor Relations
Blue Jay Gold Corp.
eric@bluejaygoldcorp.com
Phone: (604) 235-4059


Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release contain forward-looking information. Forward-looking information involves risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking information. In addition, the forward-looking statements require management to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the management’s assumptions may not be correct and that actual results may differ materially from such forward-looking statements.

These statements can be identified by the use of forward-looking terminology (e.g., “expect”,” estimates”, “intends”, “anticipates”, “believes”, “plans”). Forward-looking statements contained in this press release may include, but are not limited to, the results of the Skukum Creek drill program (including drilling of the Rainbow Zone and other areas of Steller), the timing and scope of the rest of the Company’s exploration program, and future business plans of the Company. Such information involves known and unknown risks, including the receipt of regulatory approval, the results of future financing and exploration activities, the interpretation of exploration results and other geological data, or unanticipated costs and expenses and other risks identified by Blue Jay in its public securities filings that may cause actual events to differ materially from current expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable securities laws and regulation, Blue Jay disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/13c6cc00-5441-40b1-bc19-27c5c6a877c2
https://www.globenewswire.com/NewsRoom/AttachmentNg/161f3677-c0b5-4fad-980a-214d386c90ba

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.